期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性白血病患者血浆sFas表达的实验研究 被引量：3

THE STUDIES OF THE EXPRESSION OF SOL UBL E FAS IN PATIENTS WITH ACUTE LEUKEMIA
原文传递
导出
摘要 目的 :了解急性白血病患者血浆 s Fas水平及其意义。方法 :流式细胞仪免疫荧光双标法检测 71例急性白血病患者的血浆 s Fas含量 ,并与正常对照组比较。结果 :难治复发组急性白血病患者s Fas含量 (6 .2 3μg/ L± 1.31μg/ L;n=4 4 )显著高于 (P<0 .0 1)正常对照 (4 .85 μg/ L± 0 .92 μg/ L;n=2 8)和缓解组 (5 .12 μg/ L± 1.0 8μg/ L;n=2 7)。结论 :初步提示血浆 s Objective:To explore the role of plasma soluble Fas receptor levels in patients with acute leukem ia.Methods:The levels of plasm a in71patients with acute leukemia and2 8con- trols were measured by flow cytom etry.Results:s Fas levels in refractory/ relapsed patients(6 .2 3 μg/ L± 1.31μg/ L ;n=4 4 ) were remarkably higher(P<0 .0 1) than norm al control(4 .85μg/ L± 0 .92 μg/ L;n=2 8) and complete remission(CR) subjects(5 .12 μg/ L± 1.0 8μg/ L;n=2 7) respectively. Conclusion:Increasing levels of plasma s Fas in patients suffered from acute leukemia m ay be related with drug resistance.
作者 王伟 汪洪毅 刘孟宇 赵春亭
机构地区 青岛大学医学院附属医院 青岛市人民医院
出处 《白血病．淋巴瘤》 CAS 2003年第2期86-87,共2页 Journal of Leukemia & Lymphoma
基金 青岛市科技局发展计划 ( 98-1-4 5 )
关键词 急性白血病 SFAS 受体 L eukemia s Fas Receptor
分类号 R733.71 [医药卫生—肿瘤] R730.3 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Kotani T,Aratake Y,Kondo S,et a1.Expression of functional Fas antigen in adult T—cell leukemia[J].Leukemia Res.1994.18:305—310.
  • 2Munker R, Lubbert M,Yonehara S,et al. Expression of the Fas antigen on primary human leukemia cells[J]. Ann Hematol, 1995,70:15-- 17.
  • 3Cheng J,Zhou T, Liu C, et al, Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule [J], Science,1994,263 : 1759-- 1762.
  • 4Oehm A,Behrmann l,Falk W,et al. Purification and molecularcloning of the APO-1 cell surface antigen,a member of the tumor necrosis factor/nerve growth fact or superfamily. Sequence identity with the Fas antigen[J]. J Biol Chem, 1992,267 : 10709-- 10715.
  • 5Papoff G, Cascino I, Eramo A, et al. An N-terminal domain shared by Fas/Apo(CD95) soluble variants prevents cell deathin vitro[J]. J Immunol,1996,156(12):4622--4630.
  • 6Knipping E, Debatim K M, Stricker K,et al. Identification of soluble APO-1 in supernatants of human B-and T-cell leukemias[J ]. Blood, 1995,85 : 1562 -- 1569.
  • 7Sugahara K, Yamada Y, Hiragata Y, et al, Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia(ATL) cells and ATL-cell lines[J]. Int J Cancer, 1997,72 :128--132.

同被引文献17

  • 1徐李容,刘陶文,林高娟,杨建斌.放化疗对鼻咽癌患者血清可溶性Apo-1/Fas水平的影响及其临床意义[J].肿瘤,2005,25(3):287-288. 被引量：1
  • 2Itoh N,Yonehara S,Ishil A,et al.The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis[J].Cell,1991,66(2):233-243.
  • 3Cheng J,Zhou T,Liu C,et al.Protcction from Fsa-mediated apoptosis by a soluble form of the Fas molecule[J].Science,1994,263(25):1759-1762.
  • 4Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule, cience. 1994, 263(5154): 1759-62.
  • 5Papoff G, Cascino I, Eramo A, et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro[J].J Immunol. 1996,156(12):4622-30.
  • 6Schulze-Osthoff k, Ferrari D, Los M, et al. Apoptosis signaling by death receptors[J].Eur J Biochem, 1998, 254(3): 439-59.
  • 7Bruserud O, Ulvestad E. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels [J].Cancer Immunol Immunother, 2000,49(7):377-87.
  • 8申红,张波,汪运山,史巧云.可溶性Fas与肺癌分期和转移的关系[J].山东医药,1998,38(11):3-4. 被引量：6
  • 9崔霞,刘彦娥,申红.可溶性Fas与结直肠癌转移的关系[J].齐鲁肿瘤杂志,1999,6(2):108-109. 被引量：6
  • 10仇生龙,彭志海,王裕发,黄锦湫.大肠癌患者血清可溶性Fas(sFas)水平表达[J].肿瘤,2000,20(3):195-197. 被引量：8

引证文献3

二级引证文献3

白血病．淋巴瘤
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部